bleeding Thrombocytopenia
Conditions
Interventions
one group of patients will receive platelet concentrates that have been
pathogen-reduced, the other group will receive standard (untreated) platelet
concentrates
Sponsors
Sanquin bloedvoorziening
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age * 18 years. * Expected * 2 platelet transfusion requirements. * Having a hemato-oncological disease
Exclusion criteria
Exclusion criteria: * Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP * Bleeding > grade 2 at randomization ( after treatment, the patient can be randomized in the study after 2 or more weeks after the last transfusion that was used to stop the bleeding) * Known immunological refractoriness to platelet transfusions. * HLA- and/or HPA-allo immunization and/or clinical relevant auto-antibodies. * Indications to use hyper-concentrated (plasma-reduced) platelet concentrates, i.e. patients with known severe allergic reactions and documented transfusion-associated circulatory overload (TACO) * Pregnancy (or lactating) * Prior treatment with pathogen-reduced blood products * Known allergy to riboflavin or its photoactive products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| platelet increments after transfusion, including correction for the body surface area percentage days with bleeding transfusion reactions number of red cell transfusions and platelet transfusions number of days between transfusions percentage of patients that develop antibodies relation between laboratory tests and clinical outcomes clinical factors that have an interaction with blood coagulation | — |
Countries
Netherlands
Outcome results
None listed